ResultsIQ › Latest results › Sai Parenterals Limited
Sai Parenterals Limited Q2 FY27 results press release summary
NSE: SAIPARENT · BSE: 544742
Results press release of 1 Nov 2026, summarised by AI from the filing.
Gross margin rose to 47.5% from 40.9% on tighter inventory management and FIFO controls on a new ERP.
Key takeaways
- Margin change Gross margin rose to 47.5% from 40.9% on tighter inventory management and FIFO controls on a new ERP.
- Growth driver Unit III expansion complete, capacity up from 85.5 to 155 million units a month, output ramping from Q4 FY27.
Sai Parenterals Limited Q2 FY27 results
As filed: Revenue ₹195 cr, EBITDA ₹40.2 cr, PAT ₹10.5 cr, EBITDA margin 20.6%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹195 cr). Scored once a year-earlier consolidated quarter exists.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹179 cr, EBITDA ₹23.5 cr, PAT ₹7.9 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹179 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.9% in 30 days (Nifty 500: −3.1%).
- Q4 FY26: Revenue ₹198 cr, EBITDA ₹26.1 cr, PAT ₹13.2 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹198 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +20.8% in 30 days (Nifty 500: +2.7%).
- Q3 FY26: Revenue ₹96.2 cr, EBITDA −₹3.6 cr, PAT −₹6.7 cr, EBITDA margin -3.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹96.2 cr). Scored once a year-earlier consolidated quarter exists.
Past price moves after results do not indicate future moves. Not a recommendation.
Sai Parenterals Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.